Carteolol/latanoprost

Drug Profile

Carteolol/latanoprost

Alternative Names: Carteolol hydrochloride/latanoprost; Mikeluna; OPC-1085EL

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antiglaucomas; Antihypertensives; Propanolamines; Prostaglandins; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Glaucoma; Ocular hypertension

Most Recent Events

  • 11 Jan 2017 Inouye Eye Hospital initiates enrolment in a clinical trial for Glaucoma or Ocular hypertension in Japan (UMIN000026224)
  • 11 Jan 2017 Inouye Eye Hospital initiates enrolment in a clinical trial for Glaucoma or Ocular hypertension in Japan (UMIN000026230)
  • 11 Jan 2017 Inouye Eye Hospital initiates enrolment in a clinical trial for Glaucoma or Ocular hypertension in Japan (UMIN000026231)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top